For topical use only. Not for oral, ophthalmic or intravaginal use.
- TRADE NAME: Aklief (Galderma)
- INDICATIONS: Indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
- CLASS: Retinoic acid receptors (RAR) agonist, Retinoid
- HALF-LIFE: 2–9 hours
- FDA APPROVAL DATE: 10/04/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Available data from clinical trials in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
